Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19.
Nat Nanotechnol
; 16(8): 942-951, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1275929
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has grown into a global pandemic, and only a few antiviral treatments have been approved to date. Angiotensin-converting enzyme 2 (ACE2) plays a fundamental role in SARS-CoV-2 pathogenesis because it allows viral entry into host cells. Here we show that ACE2 nanodecoys derived from human lung spheroid cells (LSCs) can bind and neutralize SARS-CoV-2 and protect the host lung cells from infection. In mice, these LSC-nanodecoys were delivered via inhalation therapy and resided in the lungs for over 72 h post-delivery. Furthermore, inhalation of the LSC-nanodecoys accelerated clearance of SARS-CoV-2 mimics from the lungs, with no observed toxicity. In cynomolgus macaques challenged with live SARS-CoV-2, four doses of these nanodecoys delivered by inhalation promoted viral clearance and reduced lung injury. Our results suggest that LSC-nanodecoys can serve as a potential therapeutic agent for treating COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Nanostructures
/
Lung Injury
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Limits:
Animals
/
Humans
Language:
English
Journal:
Nat Nanotechnol
Year:
2021
Document Type:
Article
Affiliation country:
S41565-021-00923-2
Similar
MEDLINE
...
LILACS
LIS